We’re currently experiencing extremely high call volumes. We’re very sorry for any inconvenience this might cause.

If you need help with your account, please visit our Help Centre, or email us and we’ll get back to you as soon as we can. For more information and tips on managing your account online please visit www.hl.co.uk/coronavirus

We’re experiencing high call volumes, please check FAQs before calling.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

BB Biotech AG (BION) CHF1

Sell:51.40 CHF Buy:53.50 CHF Change: 0.70 CHF (1.33%)
Market closed |  Prices as at close on 27 March 2020 | Switch to live prices |
Sell:51.40 CHF
Buy:53.50 CHF
Change: 0.70 CHF (1.33%)
Market closed |  Prices as at close on 27 March 2020 | Switch to live prices |
Sell:51.40 CHF
Buy:53.50 CHF
Change: 0.70 CHF (1.33%)
Market closed |  Prices as at close on 27 March 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Company’s portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.

Contact details

Schwertstrasse 6
+41 (52) 6240845

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
2.92 billion CHF
Shares in issue:
55.40 million
No specific industry
SIX Swiss Exchange
Swiss Franc
Swiss All Share Index

Key personnel

  • Erich Hunziker
    Chairman of the Board
  • Clive Meanwell
    Vice Chairman of the Board of Directors
  • Silvia Siegfried-Schanz
    Director of Investor Relations
  • Maria-Grazia Iten-Alderuccio
    Director of Investor Relations
  • Claude Mikkelsen
    Director of Investor Relations
  • Maurizio Bernasconi
    Member of the Investment Management Team
  • Felicia Flanigan
    Member of the Investment Management Team
  • Christian Koch
    Member of the Investment Management Team
  • Daniel Koller
    Head of the Investment Management Team
  • Stephen Taubenfeld
    Member of the Investment Management Team

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.